Has the Danish Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the Danish Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 11.3x which is lower than its 3-year average PE of 30.6x. The 3-year average PS ratio of 10.0x is higher than the industry's current PS ratio of 4.0x.

Which industries have driven the changes within the Danish Healthcare industry?

There are no additional sub-industries under this industry.

Danish (OMX) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 13 May 2026	DKK 1.4t	DKK 359.0b	DKK 126.4b	12.9x	11.2x	3.9x
Fri, 10 Apr 2026	DKK 1.1t	DKK 340.0b	DKK 106.8b	12.4x	10.7x	3.4x
Sun, 08 Mar 2026	DKK 1.2t	DKK 340.0b	DKK 106.8b	11.7x	11.1x	3.5x
Tue, 03 Feb 2026	DKK 1.7t	DKK 345.8b	DKK 108.6b	16x	16.1x	5x
Thu, 01 Jan 2026	DKK 1.5t	DKK 345.8b	DKK 108.6b	13.9x	14.2x	4.4x
Sat, 29 Nov 2025	DKK 1.5t	DKK 345.8b	DKK 108.6b	13.6x	13.8x	4.3x
Mon, 27 Oct 2025	DKK 1.6t	DKK 341.3b	DKK 115.5b	13.7x	14x	4.7x
Wed, 24 Sep 2025	DKK 1.8t	DKK 341.3b	DKK 115.5b	15x	15.2x	5.1x
Fri, 22 Aug 2025	DKK 1.7t	DKK 341.2b	DKK 115.4b	14.2x	14.4x	4.9x
Sun, 20 Jul 2025	DKK 1.9t	DKK 331.8b	DKK 108.8b	17.6x	17.6x	5.8x
Tue, 17 Jun 2025	DKK 2.3t	DKK 331.8b	DKK 108.8b	21.1x	21x	6.9x
Thu, 15 May 2025	DKK 2.0t	DKK 330.9b	DKK 108.6b	18.4x	18.3x	6x
Sat, 12 Apr 2025	DKK 1.9t	DKK 317.9b	DKK 104.9b	18.5x	18.3x	6.1x
Mon, 10 Mar 2025	DKK 2.7t	DKK 317.9b	DKK 104.9b	26.3x	25.9x	8.6x
Wed, 05 Feb 2025	DKK 2.7t	DKK 297.4b	DKK 98.1b	27.8x	27.9x	9.2x
Fri, 03 Jan 2025	DKK 2.9t	DKK 297.4b	DKK 98.2b	29.8x	29.6x	9.8x
Sun, 01 Dec 2024	DKK 3.4t	DKK 297.4b	DKK 98.2b	35.4x	34.9x	11.5x
Tue, 29 Oct 2024	DKK 3.5t	DKK 283.9b	DKK 93.2b	38x	37.5x	12.3x
Thu, 26 Sep 2024	DKK 3.8t	DKK 283.9b	DKK 93.2b	41.8x	41.2x	13.5x
Sat, 24 Aug 2024	DKK 4.1t	DKK 283.9b	DKK 93.2b	45x	44.3x	14.5x
Mon, 22 Jul 2024	DKK 4.1t	DKK 269.3b	DKK 92.2b	45x	44.4x	15.2x
Wed, 19 Jun 2024	DKK 4.4t	DKK 269.3b	DKK 92.2b	49x	48.1x	16.5x
Fri, 17 May 2024	DKK 4.1t	DKK 269.3b	DKK 92.2b	45.6x	44.9x	15.4x
Sun, 14 Apr 2024	DKK 4.0t	DKK 257.0b	DKK 86.4b	46.9x	46.1x	15.5x
Tue, 12 Mar 2024	DKK 4.1t	DKK 257.0b	DKK 86.4b	47.7x	46.9x	15.8x
Thu, 08 Feb 2024	DKK 3.7t	DKK 256.6b	DKK 86.6b	43.8x	43x	14.5x
Sat, 06 Jan 2024	DKK 3.3t	DKK 238.8b	DKK 78.2b	43x	42.1x	13.8x
Mon, 04 Dec 2023	DKK 3.2t	DKK 238.8b	DKK 78.2b	41.4x	40.5x	13.3x
Wed, 01 Nov 2023	DKK 3.1t	DKK 225.4b	DKK 70.1b	45x	43.9x	13.7x
Fri, 29 Sep 2023	DKK 3.0t	DKK 225.4b	DKK 70.1b	43.3x	42.4x	13.2x
Sun, 27 Aug 2023	DKK 2.9t	DKK 225.4b	DKK 70.1b	42.5x	41.6x	12.9x
Tue, 25 Jul 2023	DKK 2.5t	DKK 211.8b	DKK 63.8b	40.3x	39.4x	11.9x
Thu, 22 Jun 2023	DKK 2.5t	DKK 211.8b	DKK 63.8b	40.1x	39.2x	11.8x
Sat, 20 May 2023	DKK 2.6t	DKK 211.8b	DKK 63.8b	42.2x	41.3x	12.5x


DK Market	1.40%
Healthcare	3.18%
Pharma	3.29%
Pharma	3.29%

	Company	Last Price	7D	1Y	Valuation
	NOVO B Novo Nordisk	DKK 300.55	2.6% +DKK 33.5b	-30.6%	PE10.9x
	PEG Pharma Equity Group	DKK 0.08	6.3% +DKK 5.9m	-2.9%	PB3.9x

Announcement • 11h

Novo Nordisk A/S Demonstrates Wegovy Delivers Substantial Weight Loss and Health Benefits for Women Across All Menopause Stages

Novo Nordisk A/S announced data demonstrating that Wegovy (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity across reproductive life stages, from premenopausal years through the menopause transition and beyond. The findings are based on the STEP UP clinical weight management trial, the landmark SELECT clinical cardiovascular trial and one large-scale real-world evidence study, all presented at the European Congress on Obesity (ECO) 2026 in Istanbul, Türkiye. The studies show that when women with obesity lose weight with semaglutide, they improve their body composition with reduced waist circumference, indicative of less visceral fat, and they also reduce their risk of heart attacks and strokes while improving their quality of life, from migraine burden to depression and menopause symptoms. Nearly one in five women worldwide are now living with obesity, and the burden intensifies during the menopause years, when hormonal changes drive weight gain, redistribute fat to the abdomen, and increase cardiometabolic risk. During menopause years, women’s risk of heart attack rises notably and to the same level of men’s cardiovascular risk. Cardiovascular disease remains the leading cause of death in women worldwide, claiming more lives than all cancers combined. In a post-hoc analysis of the STEP UP trial, premenopausal women with obesity lost an average of 22.6% of their body weight on once-weekly high-dose Wegovy (semaglutide 7.2 mg) with over 4 in 10 (41.4%) achieving exceptional 25% or more weight loss, compared with placebo. Perimenopausal and postmenopausal women achieved weight loss of 19.7% and 19.8%, respectively. By the end of the trial (week 72), nearly half of women in all groups had shifted from obesity categories (body mass index =30 kg/m2) to the overweight (body mass index =25 kg/m2) or normal range weight categories (body mass index 18.5-24.9 kg/m2). The average waist circumference reduction was 17.5%, 15.6% and 15.3% in pre, peri, and postmenopausal women, respectively, indicating major loss of dangerous visceral fat. These findings indicate that treatment with semaglutide consistently benefits women with significant weight loss throughout all life stages and that early treatment, before the menopause transition begins, could lead to additional weight loss. In a post-hoc analysis of the SELECT trial, perimenopausal and postmenopausal women with obesity and heart disease experienced meaningful risk reductions in heart attacks, strokes and cardiovascular death. The results were consistent with the overall SELECT trial findings and showed a numerically larger risk reduction in the perimenopausal women (42% lower risk compared to placebo) compared to the postmenopausal women (13% lower risk compared to placebo), although the difference between the groups was not statistically significant. These findings suggest that semaglutide can lower the cardiovascular risks significantly in women with obesity going through menopause, regardless of their menopausal stage. As well as risks to physical health, obesity can drastically impact quality of life and is a recognised risk factor for chronic migraine – a debilitating condition that disproportionately affects women. In a 1-year US real-world study of over 34,000 women during menopause took menopausal hormone therapy alone, Wegovy alone or a combination of both. The women taking Wegovy alone versus menopausal hormone therapy alone had an average 42–45% lower risk of migraine starting six months after initiation and continuing throughout the study, and 25% lower risk of depression, compared with those who took menopausal hormone therapy alone. Findings showed that taking Wegovy with or without menopausal hormone therapy, was associated with a lower risk of migraine and depression compared to taking menopausal hormone therapy alone. Wegovy is approved as once-daily Wegovy pill (semaglutide tablet 25 mg) by the FDA and once-weekly Wegovy injection (2.4 mg and 7.2 mg) by the FDA, EMA and other regulatory authorities worldwide. The Wegovy pill is currently pending marketing approval from the EMA and other regulatory authorities. Wegovy is indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight and in the presence of at least one weight-related comorbid condition, and approved by the FDA to reduce the risk of major adverse cardiovascular events, such as death, heart attack or stroke in adults with known heart disease and either obesity or overweight. Furthermore, Wegovy injection is indicated to reduce excess body weight and maintain long-term weight reduction in paediatric patients aged 12 years and older. It is approved by the FDA for the treatment of MASH in adults with moderate to advanced liver scarring (fibrosis), but not in those with cirrhosis of the liver. Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI =30 kg/m2 without diabetes. The primary objective was to demonstrate the superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. SELECT was a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of Wegovy (semaglutide 2.4 mg) versus placebo as an adjunct to standard of care for the prevention of MACE in people with overweight or obesity and established CVD with no prior history of diabetes. People included in the trial were aged =45 years with a body mass index (BMI) of =27 kg/m2. The primary objective of the SELECT trial was to demonstrate the superiority of Wegovy compared to placebo with respect to reducing the incidence of 3-point MACE consisting of cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke.

Danish (OMX) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Novo Nordisk A/S Demonstrates Wegovy Delivers Substantial Weight Loss and Health Benefits for Women Across All Menopause Stages

First quarter 2026 earnings released

Alk-Abelló A/S Upgrades Earnings Guidance for the Full-Year 2026

Pharma Equity Group A/S announced that it expects to receive DKK 9.632073 million in funding